In one paragraphArticle in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Yuko ShirouchiDivision of Analytical Biochemistry, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan.ORCID 0000-0003-0945-2030 Hiroki ShinchiDivision of Analytical Biochemistry, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan.
Yoshimi HagaDivision of Analytical Biochemistry, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan.ORCID 0000-0001-7861-617X Yuko MishimaDepartment of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan.
Sayuri MinowaThe Cancer Chemotherapy Center, Division of Clinical Research, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan.
Tomoko TakayamaThe Cancer Chemotherapy Center, Division of Clinical Research, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan.
Shunji TakahashiCancer Bioscience/Oncotherapeutic Medicine, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.ORCID 0000-0002-5031-1953 Dai MaruyamaDepartment of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan.ORCID 0000-0003-0654-6920 Koji UedaDivision of Analytical Biochemistry, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan.ORCID 0000-0001-9066-4959 Funding
Institution of Corresponding Author Organization Internal Funding
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
biomarkerextracellular vesiclesmultiple myelomaproteomics
Identifiers
PMID41976339
PMCPMC13072286
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390